Safety evaluation of long-term use of Febuxostat/Febuxostat

Febuxostat(Febuxostat) is a drug used to treathyperuricemia. It mainly reduces the production of uric acid by inhibiting xanthine oxidase, thereby reducing the level of uric acid in the blood. This drug is widely used in the treatment of gout patients, especially those who are intolerant or uncontrollable of allopurinol (Allopurinol) therapy. However, research and clinical observations in recent years have triggered extensive discussions regarding the safety of long-term use of febuxostat, especially the potential risks that may arise from its long-term use.

Long-term use of febuxostat mainly prevents gout attacks and related complications by reducing blood uric acid levels. Studies have shown that the drug has good long-term efficacy and can significantly reduce the frequency and intensity of gout attacks in patients. However, like all drugs, febuxostat is also associated with certain side effects, and long-term use requires special attention to its safety.

Long-term use of febuxostat may be associated with an increased risk of cardiovascular disease. While some initial studies suggested a modest effect on cardiovascular events, later findings suggest that long-term use of febuxostat may increase the incidence of heart-related disease, particularly in patients with risk factors for cardiovascular disease. For example, some patients may be at greater cardiovascular risk due to problems such as high blood pressure and cardiac arrhythmias. Therefore, patients with cardiovascular disease or higher cardiovascular risk must be treated under the guidance of a physician and regularly monitored when using febuxostat.

Long-term use of febuxostat may also cause abnormal liver function. Some clinical studies have found that some patients have abnormal liver function indicators when using this drug for a long time, such as increased levels of ALT and AST. Although these changes are usually mild, patients with poor liver function, especially those with a history of liver disease, require special caution when using febuxostat and regular liver function monitoring.

Reference materials:https://www.drugs.com